Semaglutide 2.4 mg (Wegovy) Reduces Cardiovascular Risk in Overweight/Obesity with CVD
Full data from the SELECT trial offer insight into the 20% relative risk reduction associated with use of semaglutide 2.4 mg in patients with overweight or obesity and preexisting cardiovascular disease at AHA 2023.
United States Tiffanym Powell Amit Khera Campbellp Semaglutide Wegovy Matt Kohlmann Pa Michael Lincoff
Source: hcplive.com